Currently, HIF PHD inhibitors are in clinical trials for the treatment of anemia [42].Therefore, our results may provide a basis for therapeutic intervention to reduce gentamicin nephrotoxicity using HIF PHD inhibitors. This evidence concerns the gene PDC and anemia.